Efficacy and safety of Clarithromycin(CAM)/Ethambutol(EB) versus Rifampicin(RIF)/Clarithromycin(CAM)/Ethambutol(EB) in Mycobacterium avium Complex(MAC): a randomized, open-label, multicenter study
Not Applicable
- Conditions
- Mycobacterium avium Complex(MAC) without HIV
- Registration Number
- JPRN-UMIN000002819
- Lead Sponsor
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
ECOG performance status 3-4. Patients with HIV infection. Patients with history of treatment for MAC infection. Patients with any undelying disease considered tohave a significant impact on the course of treatment in this clinical study such as progressive cancer. Patients receiving immunosuppressive drug.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method chest Xray, HRCT, bacteriologic evaluation, clinical symptom
- Secondary Outcome Measures
Name Time Method the serum and intracellular concentration of Clarithromycin, Clarithromycin resistance of MAC